Priming effect of luteinizing hormone releasing factor: in-vitro and in-vivo evidence consistent with its dependence upon protein and RNA synthesis.
The aim of this study was to determine whether the priming effect of LH-RF depends upon RNA and protein synthesis. In in-vivo studies saline, actinomycin D, or cycloheximide was administered i.p. 3-5-4h before the first i.v. injection of synthetic LH-RF into pro-oestrous rats anaesthetized with sodium pentobarbitone at 13.30 h. The LH-response to the second injection of LH-RF (given 60 min after the first) was markedly reduced by the inhibitors, but the response to the first injection was not significantly affected. Studies with cycloheximide given i.v. showed that the inhibition of protein synthesis up to the second injection of LH-RF reduced the magnitude of the priming effect, the reduction being greatest when the inhibitor was administered up to 30 min after the first LH-RF injection. Pituitary incubation studies showed that the priming effect could also be elicited in vitro and that it could be significantly reduced by actinomycin D, cycloheximide and puromycin. As in vivo, the inhibitors had relatively little effect on the LH-response to the first exposure to LH-RF. The protein synthesized after an injection of LH-RF may be new LH, and/or a protein(s) concerned with 'activation' of the receptor or release components of the LH-secretory apparatus.
D000818:Animals; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology*; D007986:Luteinizing Hormone / Q000032:analysis; D010903:Pituitary Gland, Anterior / Q000378:metabolism / Q000502:physiology; D014176:Protein Biosynthesis; D011691:Puromycin / Q000494:pharmacology*; D012313:RNA / Q000096:biosynthesis*; D051381:Rats
D003609:Dactinomycin; D007987:Gonadotropin-Releasing Hormone; D011691:Puromycin; D012313:RNA; D007986:Luteinizing Hormone; D003513:Cycloheximide